REFERENCES
- Burgdorf W.H.C., Gilmore W.A., Ganick R.G. Peculiar Acral Erythema Secondary to High-Dose Chemotherapy for Acute Myelogenous Leukemia. Ann. Intern. Med. 1982; 97: 61–62
- Lokich J.J., Moore C. Chemotherapy-Associated Palmar–Plantar Erythrodysesthesia Syndrome. Ann. Intern. Med. 1984; 101: 798–800
- Baack B.R., Burgdorf W.H.C. Chemotherapy-Induced Acral Erythema. J. Am. Acad. Dermatol. 1991; 24: 457–461
- De Vries E.G., Greidanus J., Mulder N.H., , et al. A Phase I and Pharmacokinetic Study with 21-Day Continuous Infusion of Epirubicin. J. Clin. Oncol. 1987; 5: 1445–1451
- Vokes E.E., Raschko J.W., Vogelzang N.J., , et al. Five-Day Infusion of Fluorodeoxyuridine with High-Dose Oral Leucovorin: a Phase I Study. Cancer Chemother. Pharmacol. 1991; 28: 69–73
- Vukelja S.J., Baker W.J., Burris H.A. Pyridoxine Therapy for Palmar–Plantar Erythrodysesthesia Associated with Taxotere. J. Natl Cancer Inst. 1993; 85: 1432–1433
- Hoff P.M., Valero V., Ibrahim N., , et al. Hand–Foot Syndrome Following Prolonged Infusion of High Doses of Vinorelbine. Cancer 1998; 82: 965–969
- Dooley M., Goa K.L. Capecitabine. Drugs 1999; 58: 69–76
- Xeloda® (Capecitabine) Prescribing Information. Roche Laboratories, Nutley, NJ 1998
- Blum J.L., Jones S.E., Buzdar A.U., , et al. Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer. J. Clin. Oncol. 1999; 17: 485–493
- Fleiss J.L. Statistical Methods for Rates and Proportions. 2nd Ed, John Wiley and Sons, New York 1981
- 4th Ed., SAS Institute Inc., Cary, NC 1989; Vols. 1 and 2
- Budman D.R., Meropol N.J., Reigner B., , et al. Preliminary Studies of a Novel Oral Fluoropyrimidine Carbamate: Capecitabine. J. Clin. Oncol. 1998; 16: 1795–1802
- Mackean M., Planting A., Twelves C., , et al. Phase I and Pharmacologic Study of Intermittent Twice-Daily Oral Therapy with Capecitabine in Patients with Advanced and/or Metastatic Cancer. J. Clin. Oncol. 1998; 16: 2977–2985
- Cassidy J., Dirix L., Bissett D., , et al. A Phase I Study of Capecitabine in Combination with Oral Leucovorin in Patients with Intractable Solid Tumors. Clin. Cancer Res. 1998; 4: 2755–2761
- Findlay M., Van Cutsem E., Kocha W., , et al. A Randomized Phase II Study of Xeloda™ (Capecitabine) in Patients with Advanced Colorectal Cancer. Proc. Am. Soc. Clin. Oncol. 1997; 16: 227a
- Twelves C., Harper P., Van Cutsem E., , et al. A Phase III Trial (SO14796) of Xeloda™ (Capecitabine) in Previously Untreated Advanced/Metastatic Colorectal Cancer. Proc. Am. Soc. Clin. Oncol. 1999; 18: 263a
- Cox J.V., Pazdur R., Thibault A., , et al. A Phase III Trial of Xeloda™ (Capecitabine) in Previously Untreated Advanced/Metastatic Colorectal Cancer. Proc. Am. Soc. Clin. Oncol. 1999; 18: 265a
- Toxicity of Fluorouracil in Patients with Advanced Colorectal Cancer: Effect of Administration Schedule and Prognostic Factors. J. Clin. Oncol. 1998; 16: 3537–3541
- Vogelzang N.J., Ratain M.J. Cancer Chemotherapy and Skin Changes. Ann. Intern. Med. 1985; 103: 303–304
- Jones A.P., Crawford S.M. Anthracycline-Induced Toxicity Affecting Palmar and Plantar Skin. Br. J. Cancer 1989; 59: 814
- Peters W.G., Willemze R. Palmar–Plantar Skin Changes and Cytarabine. Ann. Intern. Med. 1985; 103: 805
- Gordon K.B., Tajuddin A., Guitart J., , et al. Hand–Foot Syndrome Associated with Liposome-Encapsulated Doxorubicin Therapy. Cancer 1995; 75: 2169–2173
- Diasio R.B. The Role of Dihydropyrimidine Dehydrogenase (DPD) Modulation in 5-FU Pharmacology. Oncology (Huntingt) 1998; 12(Suppl 7)23–27
- Hoff P.M., Pazdur R., Benner S.E., Canetta R. UFT and Leucovorin: A Review of Its Clinical Development and Therapeutic Potential in the Oral Treatment of Cancer. Anticancer Drugs 1998; 9: 479–490
- Vukelja S.J., Lombardo F.A., James W.D., Weiss R.B. Pyridoxine for the Palmar–Plantar Erythrodysesthesia Syndrome. Ann. Intern. Med. 1989; 111: 688–689
- Fabian C.J., Molina R., Slavik M., , et al. Pyridoxine Therapy for Palmar–Plantar Erythrodysesthesia Associated with Continuous 5-Fluorouracil Infusion. Invest. New Drugs 1990; 8: 57–63
- Gyorgy P., Eckardt R. Vitamin B6 and Skin Lesions in Rats. Nature 1939; 144: 512
- Beveridge R.A., Kales A.N., Binder R.A., , et al. Pyridoxine (B6) and Amelioration of Hand/Foot Syndrome. Proc. Am. Soc. Clin. Oncol. 1990; 9: 102a
- Vail D.M., Chun R., Thamm D.H., , et al. Efficacy of Pyridoxine to Ameliorate the Cutaneous Toxicity Associated with Doxorubicin Containing Pegylated (Stealth) Liposomes: A Randomized, Double-Blind Clinical Trial Using a Canine Model. Clin. Cancer Res. 1998; 4: 1567–1571